世界中医药

目的：观察薯蓣丸对60名术前行EC方案化疗的乳腺癌患者白细胞、Ki-67的影响，验证薯蓣丸对乳腺癌术前化疗的减毒增效作用。方法:将60例乳腺癌术前行EC方案化疗期间的患者简单随机分为中药组(30例)和对照组(30例)，中药组和对照组均行术前四个周期的化疗治疗，中药组在第三次化疗用药结束后的第1天开始服用薯蓣丸方颗粒剂至第四周期化疗结束，共30 d，对照组只常规化疗，观察患者治疗前后中医症候、白细胞的变化情况，并比较患者手术前后Ki-67变化情况。结果：1)治疗后中药组中医症候评分较对照组明显降低，差异有统计学意义(P<0.05)；2)治疗后中药组白细胞计数较对照组有明显提高，差异有统计学意义(P<0.05)；3)治疗后中药组Ki-67阳性表达率较对照组减少，差异有统计学意义(P<0.05)；结论：1)薯蓣丸可明显改善乳腺癌患者化疗期间的中医症候，提高患者生存质量;2)薯蓣丸可减轻化疗药物所致的白细胞下降，提高患者的免疫功能；3)薯蓣丸协助化疗可降低Ki-67的阳性表达率，有利于降低乳腺癌转移及复发，提高远期生存率。

English Summary:

To observe the influence of Shuyu Pill on leukocyte and Ki-67 of 60 women breast cancer patients who received EC chemotherapy before operation. Methods: The 60 patients were randomly divided into two groups: TCM group (30 cases) and control group (30 cases) and both of the group received four periods of chemotherapy. The TCM group was given Shuyu Pill after the third period of chemotherapy till finishing the fourth period, 30 days in total. The control group received regular chemotherapy. We observed the clinical symptoms of TCM and change of leukocyte after treatment, and compared the difference of Ki-67 before and after operation. Results: 1）The score on TCM clinical symptoms of TCM group was significantly lower than control group (P<0.05). 2）The number of leukocyte of patients in TCM group improved a lot comparing to the control group (P<0.05). 3）After the treatment, the positive expression rate of Ki-67 in TCM group reduced comparing to the control group (P<0.05). Conclusion: 1）Shuyu Pill could obviously improve clinical symptoms of TCM of breast cancer patients during chemotherapy and enhanced the patients life qualities. 2）Shuyu Pill could prevent decrease of the number of leukocyte due to chemotherapy and improve patients immunity. 3）Shuyu Pill could assist chemotherapy reducing positive expression rate of Ki-67. It helps preventing recurrence and metastasis of cancer and improving survival rate.

查看全文查看/发表评论下载PDF阅读器